<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00472836</url>
  </required_header>
  <id_info>
    <org_study_id>A5351038</org_study_id>
    <nct_id>NCT00472836</nct_id>
  </id_info>
  <brief_title>Study Examining The Effect Of Renal Impairment On Safety, Toleration And How The Body Processes An Experimental Drug</brief_title>
  <official_title>A Phase 1, Open-Label, Parallel Group, Multiple-Dose Study To Evaluate The Pharmacokinetics, Safety And Toleration Of CP-945,598 Administered To Subjects With Severely Impaired And Normal Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CP-945,598 is eliminated following extensive metabolism. For some drugs, decreased renal
      (kidney) function can affect their elimination from the body via metabolism. This study will
      therefore compare the pharmacokinetics (time course of drug concentrations in the body),
      safety and tolerability of CP-945,598 in patients with severe renal impairment and healthy
      control subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of drug and metabolite concentrations in serum from blood samples collected at various times over 24 hour dosing interval on Days 1 &amp; 14, before daily dose on days 2, 5-7, 13, following stopping of drug treatment on days 15-18, 21,</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>28, 35</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vital signs (blood pressure, heart rate and respiratory rate) on days 1, 2, 7, and 14</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECGs on Days 1,7 and 14</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety laboratory tests (Chemistry, hematology, urinalysis) on Days 2, 7, 14 and 35</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event monitoring throughout duration of the study</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Normal renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-945,598</intervention_name>
    <description>Administration of CP-945,598 in subjects with normal renal function.</description>
    <arm_group_label>Normal renal function</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-945,598</intervention_name>
    <description>Administration of CP-945,598 in subjects with severe renal impairment.</description>
    <arm_group_label>Severe renal impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal Subjects: 1.Healthy. 2.Matched for age (± 5 yrs), weight (± 10 kg), and gender
             ratio (± 2 subjects per gender).

          -  Subjects with Renal Disease: 1. Severe impairment (Creatinine clearance &lt;30 mL/min) 2.
             Stable renal disease:no change in the last 30 days. 3. Stable dose of medication
             and/or treatment. 4. Reasonably well-controlled type 1 and type 2 diabetics

        Exclusion Criteria:

          -  All subjects: Non-prescribed use of drugs of abuse/ recreational drugs; recent
             treatment with experimental drugs or herbal experiments; EKG and blood pressure
             parameters falling outside of protocol-specified limits; history of regular alcohol or
             tobacco use exceeding protocol-specified limits

          -  Normal subjects: Medically important health conditions; recent use of prescription or
             non-prescription medications.

          -  Subjects with renal disease: Subjects requiring dialysis; certain chronic medical
             conditions; patients who have received renal transplant; severe and/or poorly
             controlled diabetes; Treatment with protocol-specified drugs that may alter the way
             the body absorbs or processes CP-945,598.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5351038&amp;StudyName=Study%20Examining%20The%20Effect%20Of%20Renal%20Impairment%20On%20Safety%2C%20Toleration%20And%20How%20The%20Body%20Processes%20An%20Experimental%20Drug</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2007</study_first_submitted>
  <study_first_submitted_qc>May 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2007</study_first_posted>
  <disposition_first_submitted>August 11, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>August 11, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 13, 2009</disposition_first_posted>
  <last_update_submitted>August 11, 2009</last_update_submitted>
  <last_update_submitted_qc>August 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

